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Abstract
Objective: A major shortcoming in contemporary congenital heart surgery is the lack of viable replacement materials with the capacity of
growth and regeneration. Here we focused on living autologous patches engineered from human umbilical cord derived fibroblasts and
endothelial progenitor cells (EPCs) as a ready-to-use cell source for paediatric cardiovascular tissue engineering. Methods: EPCs were isolated
from 20 ml fresh umbilical cord blood by density gradient centrifugation and myofibroblasts were harvested from umbilical cord tissue. Cells
were differentiated and expanded in vitro using nutrient media containing growth factors. Before seeding, cell-phenotypes were assessed by
immuno-histochemistry. Biodegradable patches fabricated from synthetic polymers (PGA/P4HB) were seeded with myofibroblasts followed by
endothelialization with EPCs. All patches were cultured in a perfusion bioreactor. A subgroup of patches was additionally stimulated by cyclic
strain. Analysis of the neo-tissues comprised histology, immuno-histochemistry, extracellular matrix (ECM) analysis and biomechanical testing.
Results: Endothelial phenotypes of EPCs before seeding were confirmed by Ac-Dil-LDL, CD 31, von-Willebrand-Factor and eNOS staining.
Histology of the seeded patches demonstrated layered viable tissue formation in all samples. The cells in the newly formed tissues expressed
myofibroblast markers, such as desmin and alpha-SMA. The EPCs derived neo-endothelia showed constant endothelial phenotypes (CD 31, vWF).
major constituents of ECM such as collagen and proteoglycans were biochemically detected. Stress–strain properties of the patches showed
features of native-analogous tissues. Conclusions: Living tissue engineered patches can be successfully generated from human umbilical cord
derived myofibroblasts and EPCs. This new cell source may enable the tissue engineering of versatile, living, autologous replacement materials
for congenital cardiac interventions.
Q 2005 Elsevier B.V. All rights reserved.
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A major shortcoming in today’s surgery of congenital
cardiovascular defects is the lack of living replacement
materials with the capacity of growth and regeneration.
Currently, paediatric surgical treatment requires the appli-
cation of synthetic or non-autologous bioprosthetic
materials, such as patches and vascular conduits [1,2].
These materials are burdened with substantial disadvan-
tages including obstructive tissue ingrowth and calcification1010-7940/$ - see front matter Q 2005 Elsevier B.V. All rights reserved.
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growth typically cause re-operations of paediatric patients
with cardiovascular defects associated with increased
morbidity and mortality. To address the above-mentioned
problems cardiovascular tissue engineering is a new scien-
tific field aiming at in vitro fabrication of living, autologous
grafts with the capacity of growth, repair, and regeneration.
Important functional features of ideal replacement
materials for the repair of congenital defects comprise a
living matrix with native-analogous biomechanical proper-
ties and a thrombo-resistant surface. In previous studies, we
have demonstrated the feasibility of using human umbilical
cord derived myofibroblasts as a cell source for engineering
of functional paediatric tissues [4]. The umbilical cord blood
is a known source for endothelial progenitor cells (EPCs)
differentiated from haemangioblasts, a common progenitor
for both haematopoetic and endothelial cells. These cells
have the potential to differentiate into mature endothelial
cells and have been successfully utilized in non-tissueEuropean Journal of Cardio-thoracic Surgery 27 (2005) 795–800www.elsevier.com/locate/ejcts
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vessels, neo-vascularization or regeneration of ischemic
tissue [5–8] as well as coating of synthetic vascular grafts [9].
Recently, animal derived EPCs have been used for the
endothelialization of decellularized grafts in animal models
[10] and for seeding of hybrid grafts [11].
Little is known about the feasibility and utility of
umbilical cord derived EPCs for in vitro engineered endo-
thelium in humans. Here, we investigate human umbilical
cord blood derived endothelial progenitor cells (EPCs) as a
source for in vitro generation of functional endothelia
covering living tissue engineered patches as a simplified
model for pediatric cardiovascular tissue engineering.Fig. 1. Tissue engineered patch based on human umbilical cord cells.2. Material and methods
2.1. Isolation of myofibroblasts from human umbilical
cord tissue
Cells were obtained from umbilical cords of healthy
individuals after informed consent was obtained from the
participants. Myofibroblasts were isolated from umbilical
cord tissue of newborns. Several (z8 mm3) pieces of
umbilical cord tissue were washed with PBS, placed in
petri-dishes and cultured in a humidified incubator (37 8C,
5% CO2) in advanced DMEM medium (Gibco, Invitrogen)
supplemented with 10% fetal bovine serum (PAN Biotech,
Germany), 2 mM Glutamax (Gibco) and Gentamycin
(50 mg/ml, PAN). Myofibroblasts were expanded up to
passage 11.
2.2. Isolation of EPCs from human umbilical cord blood
and differentiation into endothelial phenotype
The human umbilical cord vein of newborns was
punctured directly after delivery and 20 ml of fresh blood
were obtained. Immediately, EPCs were isolated from
mononuclear cells by density gradient centrifugation
(Histopaque-1077, Sigma), followed by differential cen-
trifugation as described by Asahara et al. [12]. Isolated cells
were cultured in endothelial basal medium (EBMe-2,
Cambrex), containing growth factors and supplements
provided by the supplier: Vascular Endothelial Growth
Factor (VEGF), human Fibroblasts Growth Factor (hFGF),
human recombinant long-Insulin-like Growth Factor-1 (R3-
IGF), human Epidermal Growth Factor (hEGF), Gentamycin
and Amphotericin (GA-1000), Hydrocortisone, Heparin,
Ascorbic Acid and 2% Fetal Bovine Serum. After 4 days,
attached cells were reseeded and after 7 days the medium
was changed to EBM-2 containing the same growth factors
but 20% FBS. After 3 weeks of culturing, the endothelial
phenotype was confirmed by immuno-histochemistry. The
confluent monolayers were stained with antibodies for von
Willebrand factor (vWF, polyclonal; DAKO A/S), CD 31
(IgG1/kappa, Clone JC/70A; DAKO A/S), CD34 (IgG1, Clone
QBEND/10; Serotec) and examined for uptake of Ac-LDL
(Dil-Ac-LDL, Biomedical tech.) and expression of endo-
thelial nitric oxide synthase (eNOS, polyclonal; Transduc-
tion Laboratories, Inc.).2.3. Fabrication of scaffolds
Scaffolds were fabricated from a non-woven polyglycolic-
acid mesh with randomized distributed fibers (PGA, thick-
ness: 1.0 mm, specific gravity: 69 mg/cm3, porosity O95%,
Albany Int.), cut into 2.3 cm2 patches (Fig. 1) and coated
with Poly-4-Hydroxybutyric acid (10% w/v P4HB, TEPHA Inc.,
Cambridge, MA) by dipping. Three patches each were
attached to a ring-shaped support of 20 mm diameter and
15 mm length. After drying in an exicator, the scaffolds were
cold-gas sterilized.2.4. Seeding of scaffolds
Cells were expanded as monolayers either in 175 cm2
tissue culture flasks (TRP, Milian, Geneva, Switzerland) or in
roller bottles (Costar, 850 cm2/bottle) using the Cellroll
system (Integra biosciences) at a speed of 0.5–1 minK1. At
confluency, cells were harvested by treatment with trypsi-
n/EDTA (0.25%) and seeded onto the biodegradable
PGA/P4HB patches by using fibrin as a cell carrier [13].
Briefly, 3.5!106 cells/100 mm3 of scaffold were resus-
pended in a sterile thrombin solution (Sigma, 10 U/ml
medium) and kept on ice in a volume that equals half of
the void volume of the scaffold. The same volume of sterile,
ice-cold fibrinogen solution was added (10 mg/ml medium)
and after carefully mixing, the cells were dripped onto the
scaffold.
The patches were positioned into a bioreactor flow
system and perfused with culture medium supplemented
with 1 mM ascorbic acid-2-phosphate. After 7 days, the
cultivation conditions were altered. Patches of group 1 (nZ
9) were continued to be perfused only, while patches of
group 2 (nZ9) were additionally exposed to cyclic straining
performed about 12 mmHg resulting in a straining of 10–15%
by using a pressure applicator connected to a pressure air
chamber. After another 14 days, all patches were taken out
of the bioreactor flow system and were endothelialized with
EPCs (1.5!106 cells/cm2) on both sides. Patches were kept
at humidified incubator conditions (37 8C, 5% CO2) in EBM-2,
containing growth factors and 20% FBS. Endothelialization
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of both groups were placed back into the bioreactor flow
system and exposed for 4 subsequent days to perfusion or
perfusion and cyclic straining, respectively. After culturing,
the patches were cut into samples and portioned out for
analysis.2.5. Tissue formation analysis2.5.1. Histology
Samples were fixed in 4% phosphate buffered formalin (pH
7.0) and paraffin-embedded. Sections of 3–5 mm of each
group were examined histologically by Eosin-Hematoxylin
(H&E), Hematoxylin-Sudan (H&S), and Trichrom-Masson
staining. Selected samples were characterized by immuno-
histochemistry. Vimentin, a-SMA, and desmin were used for
analysis of the myofibroblast phenotype and vWF, CD 31 and
eNOS staining to validate the phenotype of the EPC derived
endothelial cells.2.5.2. Quantification of extracellular matrix elements
2.5.2.1. Collagen. As an indicator for collagen formation,
hydroxyproline content was determined from dried samples
as described by Huszar et al. [14]. Briefly, tissue samples
were hydrolyzed in 50–100 ml 4 M NaOH (Fluka, Switzerland)
in an autoclave at a temperature of 120 8C for 10 min. The
solution was neutralized by adding an equal volume of 1.4 M
citric acid (Fluka). Chloramin-T (Riedel-de Hae¨n (Fluka)
62 mM) was added and the samples were allowed to oxidize
for 25 min. Aldehyde/perchloric acid solution (1 M) was
subsequently added and the chromophore was allowed to
develop at 65 8C for 15 min. The absorbance of the obtained
solutions was determined at 570 nm. The amount of
hydroxyproline present in the hydrolysates was determined
from a standard curve using known amounts of trans-4-
hydroxy-L-proline (Sigma).
2.5.2.2. s-Glyco-Amino-Glycans. To further specify the extra
cellular matrix, s-Glyco-Amino-Glycans were detected col-
orimetrically using 1,9-di-methyl-methylene blue stain [15],
following complete papain digestion of the constructs in
100 mM sodium phosphate pH 6.5, 5 mM cysteine, 5 mM
EDTA and 125 mg/ml papain (Sigma).
2.5.2.3. Determination of cell number. The amount of cells
growing on the constructs was indirectly determined by
measuring the DNA content from the same papain digested
samples using Hoechst dye (Bisbenzimide H 33258, Fluka)
[16] and a fluorometer (Fluostar, BMG, Offenburg, Germany,
355 nm excitation/460 nm emmission). Calf thymus DNA
(Sigma) was used as a standard.2.5.3. Testing of mechanical properties
Measurements of the mechanical properties were per-
formed with freshly harvested patches (15!5!1 mm) using
an uniaxial tensile tester (Instron) equipped with a 10 N load
cell. Tensile stress and strain were recorded and the Young’s
modulus was calculated.3. Results
3.1. Macroscopic appearance of the patches
All patches showed homogenous tissue formation and
dense surfaces (Fig. 1).
3.2. Phenotype of myofibroblasts
Myofibroblasts showed positive staining for vimentin and
expression of alpha-SMA and desmin (Fig. 2a and b).
3.3. Morphology and phenotype of EPCs
EPCs could be isolated from all blood samples. After
isolation, the plated cells were initially rounded. After
4 days, cells were attached and formed clusters. Two
different types of EPCs were found: spindle-like shaped
cells (80%) and polymorph cells (20%). Polymorph EPCs
formed colonies and showed good growth under in vitro
conditions. After 3 weeks, they differentiated into mature
endothelial cells forming cobblestone monolayers.
Before seeding onto the scaffolds, differentiated EPCs
showed an endothelial phenotype. They stained positive for
vWF, CD 31, CD34, eNOS, and showed Ac-LDL-uptake.
Differentiated EPCs kept this phenotype when cultivated
under both cyclic strain and perfusion in the bioreactor flow
system (Fig. 2e and f).
3.3.1. Histology
Histological examination of the seeded patches revealed
good cell-to-polymer attachment. Myofibroblasts showed
good ingrowth into the PGA/P4HB scaffolds under cyclic
strain. A similar picture was observed after culturing under
perfusion. EPCs demonstrated a good attachment on the
neo-tissue formed by myofibroblasts in both groups of
culturing conditions.
H&E staining revealed organized tissue-formation with
good extracellular matrix formed by myofibroblasts in the
inner part of the patches (Fig. 2c). Trichrom–Masson-staining
highlighted elements of extracellular matrix (Fig. 2d). An
endothelial cell lining formed by differentiated EPCs was
found on surfaces of all patches. Immunohistochemistry
confirmed the endothelial phenotype of the neo-tissue
(Fig. 2e and f).
3.4. Quantification of extracellular matrix elements
A summary of the extracellular matrix composition is given
in Fig. 3. The collagen content of both groups were
comparable (strained 4.06 mg/mgG1.92, nZ8, perfused
4.21 mg/mgG0.44, nZ8). The sulfated glycosaminoglycan
content was higher in the strained than in the perfused
patches (6.44 mg/mgG1.45, nZ4 versus 4.65 mg/mgG0.61,
nZ5) and the cell number was significantly higher in the
strained patches (3.14 mg/mgG1.02, nZ4 versus 1.24G0.35,
nZ5 Student’s t-test p!0.05).
3.5. Tensile testing
Tissue engineered patches showed normal stress–strain
profiles in both groups of culturing conditions (Table 1). Only
Table 1








Strained 1 0.20 0.92 0.38
Strained 2 0.17 0.74 0.33
Strained 3 0.11 0.49 0.34
Strained 4 0.22 1.07 0.28
Strained meanGSD 0.18G0.05 0.80G025 0.33G0.04
Perfused 1 0.30 0.74 0.56
Perfused 2 0.17 0.50 0.60
Perfused 3 0.17 0.30 0.64
Perfused 4 0.08 0.24 0.50
Perfused meanGSD 0.18G0.09 0.44G0.23 0.57G0.06
Fig. 2. Histological and immunohistological characterization. Myofibroblasts
of the new tissue showed positive staining for (a) desmin and (b) a-SMA
(magnification 50!). Hemalaun & Eosin staining (c) demonstrated organized
tissue formation with production of extracellular matrix components; in
Trichrom–Masson staining (d) collagen fibres are blue (magnifications 50!).
Expression of (e) CD31 on surfaces of patches and (f) vWF, respectively
confirm the endothelial phenotype of the neo-endothelium formed by EPCs
(magnification 200!). (For interpretation of the reference to colour in this
legend, the reader is referred to the web version of this article.)
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the groups.4. Discussion
For surgical treatment of congenital cardiac defects such
as augmentation of the hypoplastic, stenotic right ventri-
cular out flow tract or the pulmonary artery in tetralogy of
Fallot, for the closure of a complete AVSD, enlargement of
the aorta in the Norwood I procedure synthetic orFig. 3. Extracellular matrix analysis. HYP, hydroxyproline; GAG, sulfated
glycosamino glycans; DNA, deoxy nucleic acid (cell number). Averages are
given in mg/mg of dry weight. The error bars represent the standard deviation.bioprosthetic replacement materials are commonly used.
Such non-autologous materials have been associated with
substantial complications including calcifications, obstruc-
tive tissue ingrowth, infections, and thrombogenicity [1,3,
17]. The availability of living graft materials with the
potential to grow, regenerate and to adapt to the changes
in the developing cardiovascular system would have funda-
mental advantages over currently used replacement
materials.
In the present study, we investigated the feasibility to
utilize human umbilical cord blood derived endothelial
progenitor cells for in vitro fabrication of living autologous
patches. We further investigated the influence of different
in vitro culture conditions on tissue maturation and
functionality of the newly formed endothelia.
As demonstrated previously [4], umbilical cord derived
myofibroblasts showed exellent ingrowth into the biode-
gradable scaffolds and organized tissue formation with the
production of extracellular matrix proteins such as collagen
and proteoglycans. This myofibroblasts based matrix for-
mation represents a crucial prerequisite for the successful
creation of mechanically competent, surgically implantable
replacement materials. Isolation of the endothelial progeni-
tor cells from umbilical cord blood samples was easily
performed and the cells were expandable in sufficient
amounts for tissue engineering purposes. After seeding,
the endothelial progenitor cells formed functional endo-
thelial layers on the surfaces of the myofibroblast derived
neo-matrices of all patches. Most importantly, the EPCs
showed constant endothelial phenotype during the whole
tissue engineering process and expressed functional features
such as eNOS. In previous studies we and others have
demonstrated that mechanical conditioning of growing
tissue engineered cardiovascular structures, such as heart
valves and blood vessels results in enhanced and more
mature tissue formation [18]. Accordingly, the patches were
cultured in a custom designed bioreactor in vitro system. We
have chosen two bioreactor protocols using flow and cyclic
strain as mechanical stimulation to increase the production
of extracellular matrix and mechanical strength of the
patches. By comparing the culture conditions, we found
higher contents of extracellular matrix proteins such as
proteoglycans as well as cell number when patches were
exposed to cyclic strain. However, collagen content was not
significantly different. These results indicate the important
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recently described by Mol et al. [19].
The mechanical profiles of all patches showed features of
native cardiovascular tissues demonstrating a non-linear
mechanical behaviour. In contrast, the scaffold material
itself exhibits linear behaviour indicating that the measured
mechanical properties are relating from the neo-tissues.
However, the mechanical strength did not reach physiologi-
cal values during the investigated in vitro time, restricting
the current patches to low-pressure applications such as in
reconstruction of the RVOT. Interestingly, we observed a
higher Young’s modulus representing a higher stiffness in the
cyclically strained compared to perfused tissues. This
difference in stiffness of the patches may result from more
mature extracellular matrix formation reflected by
increased proteoglycans content and a higher degree of
cross-links among collagen fibres to be assessed in further
experiments.
In summary, in this feasibility study we created living
autologous human patches based on umbilical cord derived
cells, representing a versatile replacement material for
congenital cardiac surgery. The endothelial progenitor cells
isolated from the umbilical cord blood showed excellent
expansion capacities, constant endothelial differentiation,
and formation of endothelia with functional properties.
Apart from being a potent cell source for differentiated
endothelial cells, human endothelial progenitor cells
may enable to use tissue engineered replacement materials
directly after birth, since they can be harvested prenatal,
e.g. by ultrasound guided chordocentesis. This approach
would provide sufficient time for the in vitro generation
of autologous replacement material ready to use at or
shortly after birth and is currently investigated in
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Mr V. Tsang (London, United Kingdom): I’m no engineer. You need to give
me a simple answer.
Presumably, your living tissue patches, in your dream, you want to use it
as a patch; is that correct?
Dr Schmidt: It’s a patch, but it’s also augmentation material, for
example, for pulmonary arteries.
Dr Tsang: So the biodegradable platform you use for the seeding of cells
would have dissolved by the time you want to use your patches; is that
correct?
Dr Schmidt: That’s correct.
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the strength. I’m sure a lot of people here do not know what that means. How
strong is it?
Dr Schmidt: We characterize the stiffness of the patches, of
the augmentation material, and found them approximating to native
tissues.
Dr Tsang: So you think it could be used in the pulmonary artery as an
augmentation patch?
Dr Schmidt: In the lower pressure system we can use it.
Dr G. Gerosa (Padova, Italy): I would like to ask you, for how long did you
keep your construct in the pulse duplicator to do some, let’s say,
preconditioning of the tissue?
Did the phenotype expression of the endothelial cells, change over this
period?
Finally, going back to the question of one of the chairmen, how pliable and
thick is this tissue?
Dr Schmidt: To your first question, we cultured the tissue and construct
for 21 days, followed by the endothelialization for additional 5 days, that is 4
weeks total culture time.And the second question, the endothelial phenotype was assessed first for
the endothelial progenitor cells also stated in the literature, we have seen a
phenotype change focusing on late endothelial progenitor cells with a
reduction of expression of specific antigens such as VEGFR-2, Ulex Lectin, CD
34. After seeding and formation of endothelia, we checked CD 31 and von
Willebrand factors detectable in mature endothelial cells.
And the last question, we measured the stiffness and elasticity of the tissue
engineered patches. The dimensions were 4 to 4 cm, and a thickness of 0.5 cm.
Dr Gerosa: So you did not experience any core necrosis in the middle of
your patch?
Dr Schmidt: No, we did not detect necrosis in the inner layer of the
patches. Obviously there was sufficient nutrient media supply in the in vitro
system.
Dr M. Haw (Southampton, United Kingdom): I was just wondering, from a
practical point of view, how long can you keep the patches alive supposing you
were growing this for clinical use? Can you keep them indefinitely?
Dr Schmidt: In the present study we have kept them in culture in our
perfusion system for 4 to 6 weeks. However, we think, if clinically necessary
we can keep them longer.
